Artbio Attracts $132M as Its Alpha Radioligand Program Moves Into the Clinic

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure

Financing co-led by new investors Sofinnova Investments and B Capital, along with an existing investor with continued support from F-Prime, Omega Funds, and...

Artbio attracts $132M as its alpha radioligand program moves into the clinic

The money is flowing this month for radiopharmaceutical companies with a presence in Europe. The latest to snag a major funding round is Artbio, which uncorked a $132 million Series B on Tuesday to move ...